Welcome to our dedicated page for Drugs Made In America Acquisition II SEC filings (Ticker: DMIIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Drugs Made In America Acquisition II's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Drugs Made In America Acquisition II's regulatory disclosures and financial reporting.
Drugs Made In America Acquisition II Corp., a Cayman Islands-based blank check company, reports its first post-IPO quarter with $500,000,000 from the sale of 50,000,000 units at $10.00 per unit placed in a U.S. trust account, plus $12,000,000 from 1,200,000 private placement units. As of September 30, 2025, the trust account balance is $500,109,355, while cash outside the trust is $315,087 and working capital is $219,011.
For the nine months ended September 30, 2025, the company recorded a net loss of $143,558, driven by $252,913 of general and administrative costs, partially offset by $109,355 of interest income on trust investments. The SPAC has not yet identified a merger target but must complete a business combination within 24 months of the IPO closing or liquidate and return funds to public shareholders.
The filing highlights substantial doubt about the company’s ability to continue as a going concern due to the fixed liquidation date and limited cash outside the trust. Management also reports material weaknesses in disclosure controls related to segregation of duties and insufficient written policies, which it is addressing while continuing its search for a pharmaceutical-sector target.
Drugs Made In America Acquisition II Corp. reported that its Chief Financial Officer and principal financial and accounting officer, Glenn Worman, resigned effective October 8, 2025, and stated his resignation was not due to any disagreement with the company’s operations, policies or practices. On November 17, 2025, the company appointed Saleem Elmasri as its new Chief Financial Officer and principal financial and accounting officer, providing his services through a Master Services Agreement with Titan Advisory Services LLC. Under this agreement, Titan Advisory Services LLC will receive
Drugs Made In America Acquisition II Corp. filed a Form 12b-25 to notify the SEC that its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will be filed late. The company explains that its financial statements could not be completed in time to obtain the required review and signatures before the normal deadline. By using this notification, it indicates that it expects to file the delayed 10-Q within the short extension period permitted under SEC Rule 12b-25.
Drugs Made In America Acquisition II Corp. reported an insider transaction on a Form 4. Director Catherine Do acquired 100,000 ordinary shares on 09/26/2025 under transaction code J.
According to the footnote, the shares were acquired from the Issuer’s sponsor, Drugs Made In America Acquisition II LLC, for no consideration. Following the transaction, the reporting person beneficially owned 100,000 shares held in direct ownership.
FAQ
What is the current stock price of Drugs Made In America Acquisition II (DMIIU)?
